Malignant Pleural Mesothelioma Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Report Overview

The Global Malignant Pleural Mesothelioma Treatment Market reached US$ 387.73 million in 2023 and is expected to reach US$ 649.83 million by 2031, growing at a CAGR of 6.8% during the forecast period 2024-2031. 

Malignant pleural mesothelioma is a very rare and aggressive form of cancer in the membrane covering the lungs and the inner side of the ribs. This neoplasm is seen in patients with occupational exposure to asbestos and the latent period between exposure and diagnosis ranges from 20 years to 40 years. MPM accounts for nearly 80% to 90% of total mesothelioma diagnoses. The common symptoms of MPM include chest pain, dry cough, shortness of breath etc. The prognosis of MPM is poor with a survival time of 12-18 months.

Market Scope

For more details on this report - Request for Sample

Market Dynamics: Drivers

Rising product development activities and regulatory approvals

Malignant pleural mesothelioma (MPM) is a rare cancer that occurs in a population with asbestos exposure. The latency period between exposure and presentation is nearly 30 years on average. Although the condition is rare with poor prognosis, several global manufacturers are developing novel drugs and some are striving to expand the applications of approved immunotherapies to MPM. These product development activities and subsequent approvals by the regulatory bodies act as a major driver for market growth in the forecast period.

For instance, on September 18, 2024, the U.S. Food and Drug Administration (FDA) approved pembrolizumab for first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy. Sold under the brand name KEYTRUDA developed by Merck is an immunotherapy drug and is currently the top-selling brand globally.

Moreover, AstraZeneca is conducting phase 3 clinical trials for Volrustomig an immunotherapy drug for unresectable pleural mesothelioma. The trial is evaluating the efficacy of Volrustomig + Carboplatin + Pemetrexed versus the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab (approved immunotherapies). The study is anticipated to be finished in the first quarter of 2028.

Restraints

The market for malignant pleural mesothelioma (MPM) treatments is restrained by several factors such as side effects associated with chemotherapy and immunotherapy, poor prognosis with the existing and novel treatment modalities, high cost of treatment, and supply chain discrepancies of chemotherapy drugs.

For more details on this report - Request for Sample

Market Segment Analysis

The global malignant pleural mesothelioma (MPM) treatment market is segmented based on type, treatment type, patient type, and region.

Immunotherapy in the treatment type segment accounted for approximately 54.4% of the global malignant pleural mesothelioma (MPM) treatment market share.

Platinum-based chemotherapy and tri-modality therapies (combination of surgery, chemotherapy, and radiation therapy) were the two major treatment modalities considered as gold standard for malignant pleural mesothelioma. However, these gold-standard therapies have several limitations and drawbacks with poor prognosis as a major one.

On the other hand, immunotherapy has evolved evidently as a revolutionary therapeutic option for cancer. Several drugs were developed and received approval for more prevalent types of cancer. Recently, the applications of immunotherapy drugs have expanded to malignant pleural mesothelioma with the approval of nivolumab plus ipilimumab in October 2020, as a first-line treatment for unresectable malignant pleural mesothelioma. Following the approval of these drugs, KEYTRUDA recently received FDA approval in September 2024 for use as a first-line treatment in combination with pemetrexed and platinum. 

Even if the treatment rate is lower for immunotherapy drugs, they reflect an overall higher market share due to their high cost. Moreover, there are several immunotherapy drugs in the pipeline, which have the scope to make a market entry in the near future. Hence the market for immunotherapy in the treatment type segment is anticipated to experience a significant growth rate in the forecasted period.

Market Geographical Share

North America dominates the global malignant pleural mesothelioma (MPM) treatment market with a share of 42.3% in 2023

North America dominates the global malignant pleural mesothelioma (MPM) treatment market due to its advanced healthcare infrastructure and facilities, easy accessibility to a variety of treatments, availability of branded drugs offered by global pharmaceutical industry leaders, etc.

The United States is well known for its advanced healthcare industry. The higher per-capita income, expenditure, and investments in the healthcare industry and stringent yet favorable regulatory policies attract the manufacturers to develop novel therapies and launch them first in the country. Patients in the U.S. are at the forefront of receiving these advanced therapies, as they are backed by favorable reimbursement policies. For instance, the combination immunotherapy Opdivo+Yervoy by  Bristol-Myers Squibb Company was first made available in the U.S., similar to the drug Keytruda by Merck. These drugs majorly generate their revenue in the North American region. Moreover, Eli Lilly generated 33.5% of Alimta (pemetrexed) revenue in 2023 from the U.S., which is far higher than any other country across the globe. Alimta is one of the most commonly used chemotherapy drugs for malignant pleural mesothelioma.

Hence, considering these factors, along with the epidemiological data and sales figures of other product categories by all market players, North America is designated as a dominant region in the global market.

Market Segmentation

By Type

• Epithelial
• Sarcomatous
• Mixed (Biphasic)

By Treatment Type

• Chemotherapy
  • Cisplatin
  • Pemetrexed
  • Others
• Immunotherapy
  • Pembrolizumab
  • Nivolumab
  • Ipilimumab
• Targeted Therapy
• Radiation Therapy
• Tri-Modality Therapy
• Surgery
  • Extra Pleural Pneumonectomy (EPP)
  • Extended Pleurectomy/Decortication (eP/D)

By Patient Type

• Male
• Female

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Market Competitive Landscape

The major players in the malignant pleural mesothelioma (MPM) treatment market include Eli Lilly and Company, Bristol-Myers Squibb Company., Accord Healthcare US., Merck & Co., Inc., Novartis AG, Pfizer Inc., MEDYRA PHARMACEUTICAL, Teva Pharmaceuticals USA, Inc., Hikma Pharmaceuticals PLC, and AstraZeneca among others.

Why Purchase the Report?

• To visualize the global malignant pleural mesothelioma (MPM) treatment market segmentation based on type, treatment type, patient type, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of malignant pleural mesothelioma (MPM) treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global malignant pleural mesothelioma (MPM) treatment market report would provide approximately 62 tables, 54 figures, and 212 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies